AtriCure, Inc.ATRC
Scheduled
AtriCure, Inc. Canaccord Genuity's 46th Annual Growth Conference
Review the key takeaways and the transcript of this earnings call.
PeriodFY 0
Key takeaways
- The company is targeting very large unmet need markets with a total addressable market (TAM) over $10 billion.
- They expect to generate $600 million plus in revenue this year and operate globally in 58 countries.
- Recent clinical trials are nearing data readouts expected by mid-next year, which could nearly triple the overall TAM.
- The long-range plan targets $1 billion in revenue by 2030 with 20% adjusted EBITDA; the company is currently ahead of plan with 17% adjusted EBITDA in the most recent quarter.
- Atrial fibrillation (AFib) affects 59 million patients and the company aims to treat 2 million cardiac surgery patients annually with their ablation and atrial clip technologies.
- The LEAPS trial (6,573 patients) and the BOX NO AF trial (1,000 patients) are the largest cardiac surgery trials ever done, focusing on stroke reduction and post-operative AFib reduction respectively.
- The pain management franchise, launched in 2019, has grown to nearly $100 million and is the fastest growing part of the business, driven by cryo nerve block technology in thoracic, sternotomy, and amputation procedures.
- The company reported beating and raising guidance in the most recent quarter, with strong top and bottom line growth and cash generation.
- Q2 growth in the pain management franchise was driven by volume (25%) and account growth (12%), with the cryosphere Max product accelerating volume growth.
- Gross margin was 77%, driven mainly by favorable product mix and geographic mix; a new manufacturing facility is expected to slightly reduce margin to around 76%.
- Operating leverage was strong with expectations for increased R&D spending in the back half of the year due to clinical trial activity.
- The company is cash flow positive and plans to continue investing in sales and R&D while maintaining bottom line progress.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Keep exploring